PT  - JOURNAL ARTICLE
AU  - Matt E. Kalaycio
TI  - Chronic myelogenous leukemia: The news you have and haven’t heard
DP  - 2001 Nov 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 913--926
VI  - 68
IP  - 11
4099  - http://www.ccjm.org/content/68/11/913.short
4100  - http://www.ccjm.org/content/68/11/913.full
SO  - Cleve Clin J Med2001 Nov 01; 68
AB  - Chronic myelogenous leukemia (CML) can usually be cured by bone marrow transplantation from matched donors. Donor T-cell activity from the graft is critical to maintaining remission. Myeloablation may not be necessary for cure. Non-myeloablative but immunosuppressive preparative regimens allow donor engraftment with less toxicity. Early combination therapy with interferon-alfa and cytarabine was the preferred option for patients who could not undergo bone marrow transplantation. Now, the advent of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, promises to change existing treatment paradigms